Allergan to buy Tobira in push for NASH treatments

Reuters Health Information: Allergan to buy Tobira in push for NASH treatments

Allergan to buy Tobira in push for NASH treatments

Last Updated: 2016-09-20

By Natalie Grover

(Reuters) - Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to $1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for nonalcoholic steatohepatitis (NASH).

This is the latest in a string of deals orchestrated by Brent Saunders, Allergan's chief executive and a seasoned dealmaker.

There are no approved medicines for NASH. Other major contenders in the race to develop a drug to treat NASH include Intercept Pharmaceuticals Inc and Genfit SA, who have drugs in late-stage development.

Conatus Pharmaceuticals Inc's treatment is in mid-stage development.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.